Sage Therapeutics (SAGE) Stock Soars on First Trading Day After IPO

NEW YORK (TheStreet) -- Sage Therapeutics  (SAGE) soared more than 60% on Friday, its first day of trading after the company's IPO.

Sage, which develops medicines to treat rare, life-threatening central nervous system disorders, priced its initial public offering of 5 million shares at $18 a share, the high end of the expected $17 to $18 range.

The stock opened at $27 and hit a high of $30.51 as of 11:37 a.m., by which point more than 3.3 million shares had changed hands.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

SAGE Price Chart SAGE Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

Jim Cramer: Some Industrials Stocks Are Becoming Great Values

Jim Cramer: Some Industrials Stocks Are Becoming Great Values

Jim Cramer Reacts to Toni Sacconaghi's Latest Tesla Note

Jim Cramer Reacts to Toni Sacconaghi's Latest Tesla Note

Howard Schultz to Jim Cramer: Starbucks Stock Is Cheap and Undervalued

Howard Schultz to Jim Cramer: Starbucks Stock Is Cheap and Undervalued